Sigrid Therapeutics Launches SiPore® Technology in the U.S. After Successful Prediabetes Study Sigrid Therapeutics has achieved U.S. market access for its SiPore® technology following the successful SHINE study, marking a significant advancement in diabetes care.

Sigrid Therapeutics Launches SiPore® Technology in the U.S. After Successful Prediabetes Study #USA #Stockholm #Sigrid_Therapeutics #SiPore_Technology #Carb_Fence